{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:52:15Z","timestamp":1791478335810,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":37,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000381","name":"Multiple Sclerosis Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000381","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008361","name":"Scleroseforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008361","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007459","name":"Multiple Sclerosis International Federation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007459","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011873","name":"Multiple Sclerosis Scientific Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011873","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007379","name":"Fondation pour l'Aide \u00e0 la Recherche sur la Scl\u00e9rose en Plaques","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007379","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000261","name":"MS Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008794","name":"Research Manitoba","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009584","name":"Toyota Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009584","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008659","name":"European Committee for Treatment and Research in Multiple Sclerosis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013465","name":"French Muscular Dystrophy Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015757","name":"Fundaci\u00f3n P\u00fablica Andaluza Progreso y Salud","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015757","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007388","name":"Compagnia di San Paolo","doi-asserted-by":"publisher","award":["MOICESS"],"award-info":[{"award-number":["MOICESS"]}],"id":[{"id":"10.13039\/100007388","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011931","name":"UK Stem Cell Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011931","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007366","name":"Fondazione Italiana Sclerosi Multipla","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007366","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004920","name":"Royan Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004920","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtct.2026.08.016","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:04:22Z","timestamp":1789517062000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of Mesenchymal Stem Cells on Peripheral Immune Cells in Multiple Sclerosis: Results from an International Phase 2 Clinical Trial"],"prefix":"10.1016","author":[{"given":"Irene","family":"Schiavetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Freedman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Thebault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Ivaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Palmeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Furlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Uccelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Laroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jtct.2026.08.016_bib0001","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s11481-013-9456-6","article-title":"Towards clinical application of mesenchymal stem cells for treatment of neurological diseases of the central nervous system","volume":"8","author":"Laroni","year":"2013","journal-title":"J Neuroimmune Pharmacol"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.016_bib0002","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.imlet.2015.08.007","article-title":"Mesenchymal stem cells for the treatment of neurological diseases: immunoregulation beyond neuroprotection","volume":"168","author":"Laroni","year":"2015","journal-title":"Immunol Lett"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.016_bib0003","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.beha.2011.01.004","article-title":"Neuroprotective features of mesenchymal stem cells","volume":"24","author":"Uccelli","year":"2011","journal-title":"Best Pract Res Clin Haematol"},{"issue":"7","key":"10.1016\/j.jtct.2026.08.016_bib0004","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1474-4422(11)70121-1","article-title":"Mesenchymal stem cells for the treatment of multiple sclerosis and other neurological diseases","volume":"10","author":"Uccelli","year":"2011","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.016_bib0005","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1474-4422(21)00301-X","article-title":"Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial","volume":"20","author":"Uccelli","year":"2021","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.016_bib0006","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/s13063-019-3346-z","article-title":"MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I\/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis","volume":"20","author":"Uccelli","year":"2019","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.016_bib0007","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s40263-021-00875-0","article-title":"Impact of natural killer (NK) cells on immune reconstitution, and their potential as a biomarker of disease activity, in alemtuzumab-treated patients with relapsing remitting multiple sclerosis: an observational study","volume":"36","author":"Palmeri","year":"2022","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.016_bib0008","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000693","article-title":"Impact of treatment on cellular immunophenotype in MS: a cross-sectional study","volume":"7","author":"Cellerino","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"7","key":"10.1016\/j.jtct.2026.08.016_bib0009","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","article-title":"B cells in multiple sclerosis\u2014from targeted depletion to immune reconstitution therapies","volume":"17","author":"Cencioni","year":"2021","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.016_bib0010","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000403","article-title":"Teriflunomide treatment reduces B cells in patients with MS","volume":"4","author":"Gandoglia","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.016_bib0011","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1182\/blood-2005-07-2657","article-title":"Human mesenchymal stem cells modulate B-cell functions","volume":"107","author":"Corcione","year":"2006","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.016_bib0012","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.exphem.2007.11.007","article-title":"Mesenchymal cells recruit and regulate T regulatory cells","volume":"36","author":"Di Ianni","year":"2008","journal-title":"Exp Hematol"},{"key":"10.1016\/j.jtct.2026.08.016_bib0013","article-title":"Differential regulation of Treg stability in human na\u00efve and effector Treg subsets by TGF\u03b2-signaling via ARKADIA-SKI axis","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.016_bib0014","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.5966\/sctm.2015-0243","article-title":"Human mesenchymal stem cells impact Th17 and Th1 responses through a prostaglandin E2 and myeloid-dependent mechanism","volume":"5","author":"Rozenberg","year":"2016","journal-title":"Stem Cells Transl Med"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.016_bib0015","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ana.22065","article-title":"Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: implication for multiple sclerosis","volume":"68","author":"Darlington","year":"2010","journal-title":"Ann Neurol"},{"issue":"14","key":"10.1016\/j.jtct.2026.08.016_bib0016","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1177\/1352458514536252","article-title":"Deficiency of CD8+ effector memory T cells is an early and persistent feature of multiple sclerosis","volume":"20","author":"Pender","year":"2014","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.016_bib0017","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1177\/1352458520951536","article-title":"Defective CD19+CD24(hi)CD38(hi) transitional B-cell function in patients with relapsing-remitting MS","volume":"27","author":"Cencioni","year":"2021","journal-title":"Mult Scler"},{"key":"10.1016\/j.jtct.2026.08.016_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577664","article-title":"Proportions of circulating transitional B cells associate with MRI activity in interferon beta-treated multiple sclerosis patients","volume":"358","author":"Mimpen","year":"2021","journal-title":"J Neuroimmunol"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.016_bib0019","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.exger.2007.05.002","article-title":"Invariant NKT and NKT-like lymphocytes: two different T cell subsets that are differentially affected by ageing","volume":"42","author":"Peralbo","year":"2007","journal-title":"Exp Gerontol"},{"issue":"5","key":"10.1016\/j.jtct.2026.08.016_bib0020","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s10067-022-06494-4","article-title":"Decreased natural killer T-like cells correlated to disease activity in systemic lupus erythematosus","volume":"42","author":"Tang","year":"2023","journal-title":"Clin Rheumatol"},{"issue":"17","key":"10.1016\/j.jtct.2026.08.016_bib0021","doi-asserted-by":"crossref","first-page":"9520","DOI":"10.3390\/ijms22179520","article-title":"NKT and NKT-like cells in autoimmune neuroinflammatory diseases\u2014multiple sclerosis, myasthenia gravis and Guillain-Barre syndrome","volume":"22","author":"Zarobkiewicz","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.jtct.2026.08.016_bib0022","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2153534","article-title":"Regulatory T cell therapy for multiple sclerosis: breaching (blood-brain) barriers","volume":"18","author":"Verreycken","year":"2022","journal-title":"Hum Vaccin Immunother"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:02:51Z","timestamp":1791475371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726006202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"alternative-id":["S2666636726006202"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.016","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Mesenchymal Stem Cells on Peripheral Immune Cells in Multiple Sclerosis: Results from an International Phase 2 Clinical Trial","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}